Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GENERIC DRUG APPROVALS INCREASE BY 41 TO 229 IN 1992; 31 ARE FIRST-TIMERS

Executive Summary

The Office of Generic Drugs' approvals of a total of 229 ANDAs and AADAs during 1992 is 41 more than were cleared by the agency in 1991 ("The Pink Sheet" Jan. 20, 1992, In Brief). OGD approved 31 drugs that were the first generic approvals of innovator products. In 1991, FDA okayed 12 first-time generic approvals. Many of the 31 first generic approvals are for equivalents of important innovator products, such as Marion Merrell Dow's Cardizem (diltiazem), Pfizer's Feldene (piroxicam), Syntex' Naprosyn (naproxen), Wyeth-Ayerst's Orudis (ketoprofen), Searle's Calan-SR/Knoll's Isoptin-SR (verapamil extended-release tabs), Tavist (clemastine fumarate), Sandoz' Pamelor (nortriptyline HCl), McNeil's Imodium-AD (loperamide), Ortho's Monistat (miconazole) and Procter & Gamble Pharmaceuticals' Macrodantin (nitrofurantoin macrocrystals). On Dec. 31, Schein's Danbury Pharmacal subsidiary gained approval for the first generic version of nitrofurantoin macrocrystals ("The Pink Sheet" Jan. 4, T&G-7). Schein said it expects to begin shipping its version of the P&G treatment for urinary tract infections in February, pending the completion of a post-approval validation inspection by FDA. Product launch will be accompanied by a four-page flier sent to 43,000 pharmacists, wholesalers and drug chain headquarters and pharmacy journal ads and a free goods program, the company said. OGD also cleared a total of 3,483 generic drug supplements in 1992, which represents 110 fewer than in 1991 when the office approved 3,593 supplements. OGD said that its backlog of overdue applications continues to go down. In fact, because OGD's workload has become more manageable, the office has been able to detail an OGD chemist to the Pilot Drug Evaluation Staff to review manufacturing supplements and to receive supplements from three ODE divisions for review ("The Pink Sheet" Oct. 5, 1992, p. 9).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS021993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel